Endocrinology and Metabolism

Original Article

Endocrine Research
Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo: Dmytro Starenki, Jong-In Park; Endocrinol Metab. 2015;30(4):593-603. Published online December 31, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.4.593

3,896 View
39 Download
16 Web of Science
15 Crossref

Background

Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the rearranged during transfection (RET) proto-oncogene. Not all patients with progressive MTC respond to current therapy inhibiting RET, demanding additional therapeutic strategies. We recently demonstrated that disrupting mitochondrial metabolism using a mitochondria-targeted agent or by depleting a mitochondrial chaperone effectively suppressed human MTC cells in culture and in mouse xenografts by inducing apoptosis and RET downregulation. These observations led us to hypothesize that mitochondria are potential therapeutic targets for MTC. This study further tests this hypothesis using1-ethyl-2-[[3-ethyl-5-(3-methylbenzothiazolin-2-yliden)]-4-oxothiazolidin-2-ylidenemethyl] pyridinium chloride (MKT-077), a water-soluble rhodocyanine dye analogue, which can selectively accumulate in mitochondria.

Methods

The effects of MKT-077 on cell proliferation, survival, expression of RET and tumor protein 53 (TP53), and mitochondrial activity were determined in the human MTC lines in culture and in mouse xenografts.

Results

MKT-077 induced cell cycle arrest in TT and MZ-CRC-1. Intriguingly, MKT-077 also induced RET downregulation and strong cell death responses in TT cells, but not in MZ-CRC-1 cells. This discrepancy was mainly due to the difference between the capacities of these cell lines to retain MKT-077 in mitochondria. The cytotoxicity of MKT-077 in TT cells was mainly attributed to oxidative stress while being independent of TP53. MKT-077 also effectively suppressed tumor growth of TT xenografts.

Conclusion

MKT-077 can suppress cell survival of certain MTC subtypes by accumulating in mitochondria and interfering with mitochondrial activity although it can also suppress cell proliferation via other mechanisms. These results consistently support the hypothesis that mitochondrial targeting has therapeutic potential for MTC.

Citations

Citations to this article as recorded by

Immunoexpression of HSPA9 and CUL2 in prostatic tissue and adenocarcinoma
Carlos Gustavo Hirth, Gislane Rocha Vasconcelos, Maria do Perpétuo Socorro Saldanha da Cunha, Carlos Heli Bezerra Leite, Conceição Aparecida Dornelas
Annals of Diagnostic Pathology.2022; 56: 151843. CrossRef
Analogs of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells
Seung-Keun Hong, Dmytro Starenki, Oleta T. Johnson, Jason E. Gestwicki, Jong-In Park
International Journal of Molecular Sciences.2022; 23(3): 1063. CrossRef
Effect of F16-Betulin Conjugate on Mitochondrial Membranes and Its Role in Cell Death Initiation
Mikhail V. Dubinin, Alena A. Semenova, Darya A. Nedopekina, Eldar V. Davletshin, Anna Yu. Spivak, Konstantin N. Belosludtsev
Membranes.2021; 11(5): 352. CrossRef
A BAG's life: Every connection matters in cancer
Elena Mariotto, Giampietro Viola, Carlo Zanon, Sanja Aveic
Pharmacology & Therapeutics.2020; 209: 107498. CrossRef
Emerging insights into mitochondria-specific targeting and drug delivering strategies: Recent milestones and therapeutic implications
Sugapriya Dhanasekaran, Divya Venugopal, Noura Al-Dayan, Vijaya Ravinayagam, Arif Ahmed Mohammed
Saudi Journal of Biological Sciences.2020; 27(12): 3581. CrossRef
Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
Pui-Kei Wu, Andrew Becker, Jong-In Park
International Journal of Molecular Sciences.2020; 21(15): 5436. CrossRef
Heat Shock Proteins (HSPs): A Novel Target for Cancer Metastasis Prevention
Vinayak Narayanankutty , Arunaksharan Narayanankutty, Anusree Nair
Current Drug Targets.2019; 20(7): 727. CrossRef
Токсичність МАРК у карциномах щитоподібної залози. Механізми пригнічення сигнального каскаду (огляд літератури та власних даних)
B. B. Guda, V. V. Pushkarev, O. I. Kovzun, V. P. Pushkarev, M. D. Tronko
Шпитальна хірургія. Журнал імені Л. Я. Ковальчука.2019; (3): 84. CrossRef
Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells
Dmytro Starenki, Nadiya Sosonkina, Seung-Keun Hong, Ricardo V. Lloyd, Jong-In Park
International Journal of Molecular Sciences.2019; 20(9): 2069. CrossRef
Mitochondrial autophagosomes as a mechanism of drug resistance in breast carcinoma
Ayman N. Abunimer, Heba Mohammed, Katherine L. Cook, David R. Soto-Pantoja, Maria Mercedes Campos, Mones S. Abu-Asab
Ultrastructural Pathology.2018; 42(2): 170. CrossRef
Genotoxic Responses of Mitochondrial Oxygen Consumption Rate and Mitochondrial Semiquinone Radicals in Tumor Cells
Kumiko Yamamoto, Hironobu Yasui, Tomoki Bo, Tohru Yamamori, Wakako Hiraoka, Toshihide Yamasaki, Ken-ichi Yamada, Osamu Inanami
Applied Magnetic Resonance.2018; 49(8): 837. CrossRef
Suppression of B-RafV600E melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone
Seung-Keun Hong, Dmytro Starenki, Pui-Kei Wu, Jong-In Park
Cancer Biology & Therapy.2017; 18(2): 106. CrossRef
Mitochondria chaperone GRP75 moonlighting as a cell cycle controller to derail endocytosis provides an opportunity for nanomicrosphere intracellular delivery
Zhihui Gao, Xiuran Niu, Qing Zhang, Hang Chen, Aiai Gao, Shanshan Qi, Rong Xiang, Mattias Belting, Sihe Zhang
Oncotarget.2017; 8(35): 58536. CrossRef
Targeted Therapy for Medullary Thyroid Cancer: A Review
S. R. Priya, Chandra Shekhar Dravid, Raghunadharao Digumarti, Mitali Dandekar
Frontiers in Oncology.2017;[Epub] CrossRef
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells
Dmytro Starenki, Seung-Keun Hong, Pui-Kei Wu, Jong-In Park
Cancer Biology & Therapy.2017; 18(7): 473. CrossRef

First
Prev
Page of 1
Next
Last

Search